What it is
A synthetic tripeptide (Lys-Glu-Asp) developed in Russia as a Khavinson short peptide intended to target vascular tissue.
How it works
Hypothesized in preclinical studies to modulate gene expression in endothelial and vascular smooth muscle cells, though human pharmacokinetics are poorly characterized.
Where it's used
Studied in Russian research literature for proposed vascular and endothelial effects; not approved as a drug outside that context.
Regulatory status
Not FDA-approved; research compound.
Reconstitution
Supplied as a lyophilized powder requiring reconstitution with bacteriostatic water prior to use.
Tracking it
Vesugen is injectable, so two things matter in a log: when you dosed and where. Rotating sites and writing both down prevents the classic “did I already pin the left side?” problem.
Source
Public reference
Last reviewed 2026-06-11